Nutritional Status Affects Long Term Survival After Lobectomy for Lung Cancer
Overview
Authors
Affiliations
Study Objectives: Nutritional status has been reported as a predictor of complications following surgery for lung cancer. However, the impact of impaired nutrition in the long term has not been extensively studied. We have analysed our own experience after lobectomy for non-small cell lung cancer (NSCLC).
Patients: Six hundred and forty-two consecutive patients undergoing lobectomy for primary lung cancer in a single centre between October 1991 and April 2004 were included in the study.
Study Design: Impaired nutritional status was defined as any of low pre-operative albumin level (less than 30g/L), recent history of weight loss or low body mass index (BMI)--less than 18.5kg/m(2). There were 400 males and 242 females, median age 66 (range 32-89 years). Outcomes studied were hospital mortality and complications, and long term survival.
Results: A high proportion of patients (185 of 642, 28%) were classed as having poor nutritional status. There were 12 hospital deaths (1.9%). Nutritional depletion had no significant impact on hospital mortality (1.3% versus 2.7%), cardiac (14.4% versus 16.8%), or respiratory (17.5% versus 18.9%) complications. The overall median survival was 48+/-6 months (standard error). On Cox multivariate analysis, impaired nutritional status, tumour stage and need for en bloc chest wall excision were all independent predictors of survival.
Conclusions: Nutritional status does not appear to significantly influence immediate outcomes following lobectomy for lung cancer. However, it is a predictor of survival in the long term independently of tumour extension and staging.
Prediction of Poor Outcome Using the Urea to Albumin Ratio in Thoracic Empyema.
Dimitrov E, Valchev D, Minkov G, Enchev E, Yovtchev Y Acta Med Litu. 2024; 31(1):160-168.
PMID: 38978860 PMC: 11227693. DOI: 10.15388/Amed.2024.31.1.21.
Albumin‑bilirubin grade is an independent prognostic factor for small lung cell cancer.
Liu S, Zhao Q, Wang Z, Zhao B, Zhang X Mol Clin Oncol. 2024; 20(2):12.
PMID: 38213660 PMC: 10777464. DOI: 10.3892/mco.2023.2710.
Blood Biomarkers of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Alfranca Y, Garcia M, Gomez Rueda A, Alvarez Ballesteros P, Rodriguez D, Torres Velasco M J Clin Med. 2022; 11(11).
PMID: 35683629 PMC: 9181575. DOI: 10.3390/jcm11113245.
The Potential Role of Nutrition in Lung Cancer Establishment and Progression.
Porro C, La Torre M, Tartaglia N, Benameur T, Santini M, Ambrosi A Life (Basel). 2022; 12(2).
PMID: 35207557 PMC: 8877211. DOI: 10.3390/life12020270.
Schussler O, Bobbio A, Dermine H, Lupo A, Damotte D, Lecarpentier Y Cancers (Basel). 2022; 14(4).
PMID: 35205621 PMC: 8870355. DOI: 10.3390/cancers14040874.